Close

Galectin Therapeutics (GALT) May Have Best Read-Through From Allergan's Tobira (TBRA) Deal - H.C. Wainwright's Arce

Go back to Galectin Therapeutics (GALT) May Have Best Read-Through From Allergan's Tobira (TBRA) Deal - H.C. Wainwright's Arce

Galmed Pharma (GLMD) Adds to NASH-Frenzy Gains

September 22, 2016 3:28 PM EDT

NASH stock Galmed Pharma (NASDAQ: GLMD) is pushing to the highs of the session. Shares are up 16.8% to $5.42, and up 43% since Tuesday when Allergan (NASDAQ: AGN) agreed to acquire Tobira Therapeutics (NASDAQ: TBRA) at a... More

Galectin Therapeutics (GALT) Adds to Recent Speculative Gains

September 22, 2016 8:19 AM EDT

Galectin Therapeutics (NASDAQ: GALT) adds to recent gains amid NASH stock takeover speculation following Allergen's (NYSE: AGN) recent takeover of Tobira (NASDAQ: TBRA) at a huge... More

Galectin Therapeutics (GALT) Gains Again on Takeover, NASH Trial Speculation

September 21, 2016 10:53 AM EDT

Galectin Therapeutics (NASDAQ: GALT) is surging higher again as speculators reprice NASH stocks following Allergen's (NYSE: AGN) takeover of Tobira (NASDAQ: TBRA) yesterday. Today, on its call, Allergan's CEO said Tobira was a 'very... More